Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a US-based clinical-stage biopharmaceutical company, announced on Friday that it has named Steve Sabus as its new chief commercial officer, effective 5 December 2022.

In the new role, Sabus will manage all commercial functions, including the development of critical launch initiatives, sales planning and commercial strategy.

Sabus has over 30 years of commercial experience launching drugs and building sales and marketing organisations within the biopharmaceutical industry. He has held the position of chief commercial officer at Turning Point Therapeutics. He has served in senior commercial roles at Astellas Pharma for over 15 years, most recently serving as the head of Oncology. He has worked for 16 years at Johnson & Johnson in commercial roles of increasing responsibility.